SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-012203
Filing Date
2022-08-04
Accepted
2022-08-04 16:17:10
Documents
71
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q knsa-20220630x10q.htm   iXBRL 10-Q 2183932
2 EX-31.1 knsa-20220630xex31d1.htm EX-31.1 11329
3 EX-31.2 knsa-20220630xex31d2.htm EX-31.2 10485
4 EX-32.1 knsa-20220630xex32d1.htm EX-32.1 6291
5 EX-32.2 knsa-20220630xex32d2.htm EX-32.2 6265
  Complete submission text file 0001558370-22-012203.txt   7628645

Data Files

Seq Description Document Type Size
6 EX-101.SCH knsa-20220630.xsd EX-101.SCH 49539
7 EX-101.CAL knsa-20220630_cal.xml EX-101.CAL 48768
8 EX-101.DEF knsa-20220630_def.xml EX-101.DEF 251702
9 EX-101.LAB knsa-20220630_lab.xml EX-101.LAB 430306
10 EX-101.PRE knsa-20220630_pre.xml EX-101.PRE 357925
65 EXTRACTED XBRL INSTANCE DOCUMENT knsa-20220630x10q_htm.xml XML 1221283
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 7814399100
Kiniksa Pharmaceuticals, Ltd. (Filer) CIK: 0001730430 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38492 | Film No.: 221136823
SIC: 2834 Pharmaceutical Preparations